AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15983798 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 11921330 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian cancer survivors
Number of subjects: 49
Study 10659924 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estrogen (estradiol 50 microg/day) combined with oral medroxyprogesterone acetate (MPA) 10 mg/day for 12 days/month
Number of subjects: 38
Study 10659924 — intervention group
Group type: COMPARATOR
Intervention: Tibolone tablets 2.5 mg/day
Number of subjects: 38
Study 7626294 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponsky‐Gauderer type
Number of subjects: 44
Study 7626294 — intervention group
Group type: COMPARATOR
Intervention: Sachs‐Vine gastrostomy
Number of subjects: 44
Study 7626294 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 44
Study 2695475 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 14
Study 2695475 — intervention group
Group type: COMPARATOR
Intervention: Control (various types)
Number of subjects: 14
Study 835502 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat diet (70% fat, 20% protein, 10% carbohydrate)
Number of subjects: 10
Study 835502 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbohydrate diet (70% carbohydrate, 20% protein, 10% fat)
Number of subjects: 10
Study 835502 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbohydrate diet
Number of subjects: 10
Study 835502 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat diet
Number of subjects: 10
Study 31393444 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular Retinalamin injections
Number of subjects: 180
Study 31393444 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 180
Study 27207089 — intervention group
Group type: EXPERIMENTAL
Intervention: Causal beliefs regarding depression
Number of subjects: 77
Study 26105520 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate extract (PE) 900 mg daily before surgery
Number of subjects: 35
Study 26105520 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PE intake)
Number of subjects: 35
Study 26105520 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate extract (PE)
Number of subjects: 35
Study 23182608 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 0.25 μg/kg
Number of subjects: 75
Study 23182608 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 0.50 μg/kg
Number of subjects: 75
Study 23182608 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 0.75 μg/kg
Number of subjects: 75
Study 23182608 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 1.0 μg/kg
Number of subjects: 75
Study 23182608 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 1.25 μg/kg
Number of subjects: 75
Study 23182608 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 75
Study 21653300 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group physicians
Number of subjects: 88000
Study 21653300 — intervention group
Group type: COMPARATOR
Intervention: Control group physicians
Number of subjects: 88000
Study 19201627 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel matrix derivative
Number of subjects: 90
Study 19201627 — intervention group
Group type: COMPARATOR
Intervention: Calcium hydroxide
Number of subjects: 90
Study 16639483 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone sparing agents (hormone therapy, bisphosphonates, PTH 1‐34)
Number of subjects: 0
Study 16639483 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonates (alendronate, risedronate)
Number of subjects: 0
Study 15309591 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg rofecoxib
Number of subjects: 62
Study 15309591 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 11547741 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery plus postoperative chemoradiotherapy
Number of subjects: 556
Study 11547741 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 556
Study 9261583 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis with cefazolin
Number of subjects: 280
Study 9261583 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 280
Study 9261583 — intervention group
Group type: COMPARATOR
Intervention: Open cholecystectomy
Number of subjects: 280
Study 9261583 — intervention group
Group type: EXPERIMENTAL
Intervention: Clean-contaminated surgery
Number of subjects: 280
Study 9261583 — intervention group
Group type: EXPERIMENTAL
Intervention: Contaminated surgery
Number of subjects: 280
Study 9261583 — intervention group
Group type: EXPERIMENTAL
Intervention: Dirty surgery
Number of subjects: 280
Study 9261583 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with septic complications
Number of subjects: 280
Study 9261583 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without septic complications
Number of subjects: 280
Study 9261583 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without infection
Number of subjects: 280
Study 9261583 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with infection
Number of subjects: 280
Study 9261583 — intervention group
Group type: EXPERIMENTAL
Intervention: Sepsis-related death
Number of subjects: 280
Study 8337215 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium lactate infusion during panic attack
Number of subjects: 0
Study 3013442 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy (M) with VAC (vincristine, doxorubicin, and cyclophosphamide) at a lower dosage, given every 4 weeks for 8 courses.
Number of subjects: 309
Study 3013442 — intervention group
Group type: COMPARATOR
Intervention: No maintenance chemotherapy (NM), no further treatment until relapse.
Number of subjects: 309
Study 3013442 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable (for limited disease patients).
Number of subjects: 309
Study 29556792 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention (16 weeks)
Number of subjects: 103
Study 29556792 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 103
Study 26376111 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg PD‐0360324
Number of subjects: 28
Study 26376111 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg PD‐0360324
Number of subjects: 28
Study 26376111 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 26376111 — intervention group
Group type: EXPERIMENTAL
Intervention: PD‐0360324 (both doses)
Number of subjects: 28
Study 23983177 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Number of subjects: 609
Study 23983177 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 609
Study 21208766 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronome-guided CPR at 80 ticks/min
Number of subjects: 0
Study 21208766 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronome-guided CPR at 100 ticks/min
Number of subjects: 0
Study 21208766 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronome-guided CPR at 120 ticks/min
Number of subjects: 0
Study 21208766 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronome-guided CPR at 140 ticks/min
Number of subjects: 0
Study 21208766 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronome guidance (general)
Number of subjects: 0
Study 20455761 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonnucleoside reverse transcriptase inhibitors (NNRTIs) - nevirapine (NVP) and efavirenz (EFV)
Number of subjects: 136
Study 18670379 — intervention group
Group type: EXPERIMENTAL
Intervention: Eversion Carotid Endarterectomy (EEA)
Number of subjects: 201
Study 18670379 — intervention group
Group type: COMPARATOR
Intervention: Conventional Carotid Endarterectomy (CEA)
Number of subjects: 201
Study 15749485 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) 50 mg on days 5-9
Number of subjects: 31
Study 15749485 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous menstrual cycles (Control)
Number of subjects: 31
Study 12605581 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute smoking
Number of subjects: 12
Study 12605581 — intervention group
Group type: COMPARATOR
Intervention: Sham smoking
Number of subjects: 12
Study 11025237 — intervention group
Group type: EXPERIMENTAL
Intervention: Subarachnoid injection of 12 mg hyperbaric bupivacaine
Number of subjects: 30
Study 11025237 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia only
Number of subjects: 30
Study 11025237 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 9122535 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 10 mg
Number of subjects: 67
Study 9122535 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg
Number of subjects: 67
Study 1900010 — intervention group
Group type: EXPERIMENTAL
Intervention: rt-PA
Number of subjects: 101
Study 1900010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 6666218 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (40 mg orally every 6 h for 3 months)
Number of subjects: 30
Study 6666218 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 6666218 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (initial dose of 40 mg orally)
Number of subjects: 30
Study 6666218 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic oral isosorbide dinitrate (40 mg every 6 h)
Number of subjects: 30
Study 30472749 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol/betamethasone dipropionate (Cal/BD) aerosol foam (0.005%/0.05%) for 4 weeks
Number of subjects: 749
Study 29542262 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive counseling, pharmacotherapy, text‐messaging, and financial incentives
Number of subjects: 29
Study 29542262 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (brief counseling)
Number of subjects: 29
Study 26718807 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge-based and skills-based training programme for physicians
Number of subjects: 1124
Study 26718807 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention (control group)
Number of subjects: 1124
Study 24737912 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab 50 mg
Number of subjects: 356
Study 24737912 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab 100 mg
Number of subjects: 356
Study 24737912 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab (both dosages)
Number of subjects: 356
Study 24737912 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 356
Study 22956863 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg PBE supplementation once daily
Number of subjects: 112
Study 22956863 — intervention group
Group type: COMPARATOR
Intervention: 40 mg PBE supplementation once daily
Number of subjects: 112
Study 19262226 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 8611
Study 19262226 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 8611
Study 17532750 — intervention group
Group type: EXPERIMENTAL
Intervention: TCL/MMF (n=180)
Number of subjects: 290
Study 17532750 — intervention group
Group type: COMPARATOR
Intervention: CsA/MMF (n=110)
Number of subjects: 290
Study 17532750 — intervention group
Group type: EXPERIMENTAL
Intervention: MMF dose, MPA‐AUC, and the 2 h AUCs of MPAG and AcMPAG
Number of subjects: 290
Study 17532750 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma AcMPAG and MPAG concentrations
Number of subjects: 290
Study 17532750 — intervention group
Group type: EXPERIMENTAL
Intervention: MPA‐AUC
Number of subjects: 290
Study 15114202 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampofol
Number of subjects: 60
Study 15114202 — intervention group
Group type: COMPARATOR
Intervention: Diprivan
Number of subjects: 60
Study 11170129 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-tocopherol
Number of subjects: 200
Study 11170129 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 200
Study 9775542 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory substitution using a personal computer connected to a miniature head-fixed video camera and headphones for real-time image processing and auditory signal generation.
Number of subjects: 0
Study 8153225 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy counseling including abortion information
Number of subjects: 79
Study 8153225 — intervention group
Group type: COMPARATOR
Intervention: Pregnancy counseling excluding abortion information
Number of subjects: 79
Study 8153225 — intervention group
Group type: COMPARATOR
Intervention: Pregnancy counseling excluding abortion information with reminder of the 'gag rule'
Number of subjects: 79
Study 3347071 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of diphenhydramine and 300 mg of cimetidine
Number of subjects: 0
Study 3347071 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 0
Study 30463394 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intakes during pregnancy
Number of subjects: 702
Study 30463394 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary recommendations adherence
Number of subjects: 702
Study 30463394 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary variables
Number of subjects: 702
Study 27618657 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic exocrine replacement therapy (PERT) consisting of 6-9 capsules of pancreatin (457.7 mg/capsule), taken two capsules three times daily during main meals and one capsule up to three times daily for snacks
Number of subjects: 67
Study 24099824 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave lithotripsy (ESWL) for calcium oxalate monohydrate (COM) calculi
Number of subjects: 193
Study 24099824 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave lithotripsy (ESWL) for mixed oxalate (COMix) calculi
Number of subjects: 193
Study 24099824 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave lithotripsy (ESWL) for carbonate apatite (CA) calculi
Number of subjects: 193
Study 24099824 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave lithotripsy (ESWL) for uric acid (UA) calculi
Number of subjects: 193
Study 22486159 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushed chlorthalidone
Number of subjects: 20
Study 22486159 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushed hydrochlorothiazide
Number of subjects: 20
Study 22486159 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushed lisinopril
Number of subjects: 20
Study 22486159 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushed lercanidipine
Number of subjects: 20
Study 22486159 — intervention group
Group type: COMPARATOR
Intervention: Crushed atenolol
Number of subjects: 20
Study 22486159 — intervention group
Group type: COMPARATOR
Intervention: Crushed bisoprolol
Number of subjects: 20
Study 22486159 — intervention group
Group type: COMPARATOR
Intervention: Crushed enalapril
Number of subjects: 20
Study 22486159 — intervention group
Group type: COMPARATOR
Intervention: Crushed ramipril
Number of subjects: 20
Study 22486159 — intervention group
Group type: COMPARATOR
Intervention: Crushed amlodipine
Number of subjects: 20
Study 20618098 — intervention group
Group type: EXPERIMENTAL
Intervention: Honey (HG)
Number of subjects: 139
Study 20618098 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 139
Study 20618098 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan (DMG)
Number of subjects: 139
Study 20618098 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine (DPHG)
Number of subjects: 139
Study 18598124 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical cord arterial blood pH levels (pHa) at delivery
Number of subjects: 0
Study 18598124 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical cord arterial blood pH levels (pHa) at delivery (subset with pHa <= 7.20)
Number of subjects: 0
Study 15800160 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan depletion
Number of subjects: 47
Study 15800160 — intervention group
Group type: COMPARATOR
Intervention: Sham depletion
Number of subjects: 47
Study 12419743 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone 12 mg/m(2)
Number of subjects: 260
Study 12419743 — intervention group
Group type: COMPARATOR
Intervention: Combination chemotherapy (FEC: fluorouracil 500 mg/m(2), epirubicin 50 mg/m(2), cyclophosphamide 500 mg/m(2))
Number of subjects: 260
Study 12419743 — intervention group
Group type: COMPARATOR
Intervention: Combination chemotherapy (FEC)
Number of subjects: 260
Study 10336110 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0
Study 10336110 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone
Number of subjects: 0
Study 10336110 — intervention group
Group type: EXPERIMENTAL
Intervention: Phen/fen (phentermine and fenfluramine)
Number of subjects: 0
Study 10336110 — intervention group
Group type: COMPARATOR
Intervention: Multivitamin
Number of subjects: 0
Study 7582281 — intervention group
Group type: EXPERIMENTAL
Intervention: salbutamol, 200 micrograms four times per day
Number of subjects: 13
Study 7582281 — intervention group
Group type: EXPERIMENTAL
Intervention: budesonide, 400 micrograms four times per day
Number of subjects: 13
Study 7582281 — intervention group
Group type: EXPERIMENTAL
Intervention: salbutamol and budesonide combination
Number of subjects: 13
Study 7582281 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 13
Study 2116678 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor physical training programme
Number of subjects: 36
Study 7247638 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyographic (EMG) feedback
Number of subjects: 48
Study 7247638 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined EMG and theta feedback
Number of subjects: 48
Study 7247638 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensorimotor rhythm (SMR) feedback
Number of subjects: 48
Study 7247638 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 48
Study 30887764 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive pill (OCP)
Number of subjects: 309
Study 30887764 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic OCP
Number of subjects: 309
Study 30887764 — intervention group
Group type: EXPERIMENTAL
Intervention: OCP
Number of subjects: 309
Study 27998620 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab, an interleukin‐6 receptor‐alpha inhibitor
Number of subjects: 251
Study 25917295 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Short-Term Dynamic (ISTDP) residential treatment program
Number of subjects: 60
Study 25917295 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (wait-list control)
Number of subjects: 60
Study 23890779 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunomagnetically purged PBSC
Number of subjects: 486
Study 23890779 — intervention group
Group type: COMPARATOR
Intervention: Non-purged PBSC
Number of subjects: 486
Study 23890779 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 486
Study 23890779 — intervention group
Group type: EXPERIMENTAL
Intervention: Purged PBSC
Number of subjects: 486
Study 21891885 — intervention group
Group type: COMPARATOR
Intervention: Conventional heat‐polymerization technique
Number of subjects: 20
Study 21891885 — intervention group
Group type: EXPERIMENTAL
Intervention: RS tension system
Number of subjects: 20
Study 19524334 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy (ERT) with agalsidase alpha or agalsidase beta
Number of subjects: 0
Study 19524334 — intervention group
Group type: COMPARATOR
Intervention: Enzyme replacement therapy (ERT)
Number of subjects: 0
Study 15994387 — intervention group
Group type: EXPERIMENTAL
Intervention: eformoterol 12 microg b.i.d.
Number of subjects: 58
Study 15994387 — intervention group
Group type: EXPERIMENTAL
Intervention: fluticasone 250 microg b.i.d.
Number of subjects: 58
Study 15994387 — intervention group
Group type: EXPERIMENTAL
Intervention: montelukast 10 mg q.d.
Number of subjects: 58
Study 12568841 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate oral contraceptive start
Number of subjects: 113
Study 12568841 — intervention group
Group type: COMPARATOR
Intervention: Conventional oral contraceptive start
Number of subjects: 113
Study 10235086 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 81 mg/day
Number of subjects: 723
Study 10235086 — intervention group
Group type: EXPERIMENTAL
Intervention: Trapidil 300 mg/day
Number of subjects: 723
Study 10235086 — intervention group
Group type: COMPARATOR
Intervention: No antiplatelets
Number of subjects: 723
Study 8909381 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐rHuMGDF 0.03 microgram/kg
Number of subjects: 17
Study 8909381 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐rHuMGDF 0.1 microgram/kg
Number of subjects: 17
Study 8909381 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐rHuMGDF 0.3 microgram/kg
Number of subjects: 17
Study 8909381 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐rHuMGDF 1.0 microgram/kg
Number of subjects: 17
Study 8909381 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 1757831 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal suction with saline instillation (0.25-0.5 ml)
Number of subjects: 27
Study 1757831 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal suction without saline instillation
Number of subjects: 27
Study 6624697 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha‐tocopherol supplement of 800 IU
Number of subjects: 59
Study 6624697 — intervention group
Group type: EXPERIMENTAL
Intervention: beta‐carotene supplement of 30 mg (5000 retinol equivalents)
Number of subjects: 59
Study 6624697 — intervention group
Group type: EXPERIMENTAL
Intervention: retinyl palmitate supplement of 25,000 IU (13,750 retinol equivalents)
Number of subjects: 59
Study 31337365 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated network approach of preventive care for overweight children
Number of subjects: 180
Study 31337365 — intervention group
Group type: COMPARATOR
Intervention: Control group (overweight or obese children outside 's-Hertogenbosch)
Number of subjects: 180